As a medium-potency topical corticosteroid with a fast onset of action, Elocon (mometasone furoate; Merck & Co/Shionogi) is among the most frequently prescribed corticosteroids for the treatment of atopic dermatitis, across all levels of disease severity. While dermatologists are satisfied with Elocon’s efficacy in atopic dermatitis, Datamonitor Healthcare forecasts the drug to face competition from Anacor Pharmaceuticals’ novel phosphodiesterase 4 (PDE4) inhibitor crisaborole, which is expected to target mild and moderate patients, should it be approved and launched. As a non-steroidal topical agent, crisaborole will particularly appeal to patients who are concerned about the side effects associated with steroid use.
Elocon is a topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including atopic dermatitis, in patients aged two years and older. While the mechanism of the anti-inflammatory activity of topical corticosteroids remains unclear, studies suggest that corticosteroids stimulate the production of lipocortins, a group of phospholipase A2 inhibitory proteins. Lipocortins are thought to block the production of inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid by phospholipase A2 (Elocon prescribing information, 2013; Kraqballe, 1989).
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Elocon : Atopic dermatitis
LIST OF FIGURES
6 Figure 1: Elocon for atopic dermatitis – SWOT analysis
7 Figure 2: Datamonitor Healthcare’s drug assessment summary of Elocon in atopic dermatitis
8 Figure 3: Datamonitor Healthcare’s drug assessment summary of Elocon in atopic dermatitis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.